| Autor: |
Hellyer, Thomas P, Morris, Andrew Conway, McAuley, Daniel F, Walsh, Timothy S, Anderson, Niall H, Singh, Suveer, Dark, Paul, Roy, Alistair I, Baudouin, Simon V, Wright, Stephen E, Perkins, Gavin D, Kefala, Kallirroi, Jeffels, Melinda, McMullan, Ronan, O'Kane, Cecilia M, Spencer, Craig, Laha, Shondipon, Robin, Nicole, Gossain, Savita, Gould, Kate, Ruchaud-Sparagano, Marie-Hélène, Scott, Jonathan, Browne, Emma M, MacFarlane, James G, Wiscombe, Sarah, Widdrington, John D, Dimmick, Ian, Laurenson, Ian F, Nauwelaers, Frans, Simpson, A John |
| Předmět: |
|
| Popis: |
BACKGROUND: Excessive use of empirical antibiotics is common in critically ill patients. Rapid biomarker-based exclusion of infection may improve antibiotic stewardship in ventilator-acquired pneumonia (VAP). However, successful validation of the usefulness of potential markers in this setting is exceptionally rare. OBJECTIVES: We sought to validate the capacity for specific host inflammatory mediators to exclude pneumonia in patients with suspected VAP. METHODS: A prospective, multicentre, validation study of patients with suspected VAP was conducted in 12 intensive care units. VAP was confirmed following bronchoscopy by culture of a potential pathogen in bronchoalveolar lavage fluid (BALF) at >10(4) colony forming units per millilitre (cfu/mL). Interleukin-1 beta (IL-1β), IL-8, matrix metalloproteinase-8 (MMP-8), MMP-9 and human neutrophil elastase (HNE) were quantified in BALF. Diagnostic utility was determined for biomarkers individually and in combination. RESULTS: Paired BALF culture and biomarker results were available for 150 patients. 53 patients (35%) had VAP and 97 (65%) patients formed the non-VAP group. All biomarkers were significantly higher in the VAP group (p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
